Concentrations of vasoactive intestinal polypeptide were measured in blood drawn from the cavernous spaces of corpus cavernosum of the human penis during tumescence and erection, and the effect of injecting the polypeptide into the cavernous spaces was studied. A significant release of the polypeptide was shown during
between successive cycles in the same subject. Nevertheless, with occasional exceptions4 9 11-13 there are very few published data which can be described as greatly superior. We do not seek to present arguments for or against the existence of the accepted clinical concepts. We are not aware of any previous attempts to define ranges in this manner, even though several cut off points have been described, ranging from 9-6 nmol/l (3-0 ng/ml)14 to 38 nmol/l (12-0 ng/ml). 13 In addition, it is worth while re-emphasising that the principles of management of anovulation and defective luteal phase are quite different. There is well accepted and effective treatment for anovulation but little or no controlled evidence that current treatment of luteal phase deficiency is of any value. Thus it is of obvious therapeutic importance to distinguish the two conditions.
Another important feature of this study is the definition of the clinical cut off points as multiples of the follicular phase median. The purpose of this is as follows. It is well known that different assay systems (especially radioimmunoassay systems using different sets of reagents) give different numerical results. Thus an individual laboratory cannot rely entirely on published normal ranges or definitions of abnormality. Equally, the smaller unit cannot do its own clinical trial to define these ranges; even the quite simple investigation described here required appreciable time and effort. It should, however, be possible for any unit to collect a small group (10-20) of samples from apparently normal subjects in the follicular phase-a process aided by the fact that values are stable over this period and exact timing is not important. A median may be derived from this set of values and the multiples of the median then used to extrapolate an upper limit for the follicular phase or "anovular" values and a range for defective luteal function. For convenience, the limits so defined may be rounded to the nearest whole number. In this way the small unit can calculate with reasonable confidence a set of clinical action lines which would otherwise require a lengthy and tedious clinical study.
Introduction
The 28 amino acid peptide vasoactive intestinal polypeptide has been found in nerve fibres throughout the body.' Evidence has been put forward that it functions as a neurotransmitter in several non-adrenergic, non-cholinergic physiological events.1 2 An essential part of the mechanism leading to penile erection is non-adrenergic, non-cholinergic relaxation of vascular and cavernous smooth muscle.36 The recent finding in the male genital tract ofnerves containing vasoactive intestinal polypeptide that seemed to innervate blood vessels,7-and the relaxant effect of the polypeptide on cavemous smooth muscle, suggest that it may act as a neurotransmitter in penile erection.
In the present study we investigated the local release of vasoactive intestinal polypeptide during erection and the effect of administering the polypeptide direct into the cavemous body.
Release of vasoactive intestinal polypeptide-Nine men (aged 24-60) participated in 12 experiments. All had given written informed consent, and the study had been approved by the local ethical committee. Two men were normal volunteers, and seven were being evaluated because of erectile dysfunction (psychogenic in two; due to vascular insufficiency in four; and neurogenic and arteriogenic (after injury) in one). Erection was induced by means of visual sexual stimulation in the two normal men6; by intracavernous injection of 80 mg papaverine in five men (one with psychogenic, four with vasculogenic dysfunction)10; and by a continuous infusion of saline in four (two with psychogenic, two with vasculogenic dysfunction)."' Two men received both infusion of saline and, later, papaverine. Blood samples were drawn from the cavernous body before and during erection for measurement of immunoreactive vasoactive intestinal polypeptide."2
The plasma concentration of the polypeptide was corrected for the dilution during the saline infusion by determination of the packed cell volume. Peripheral venous blood samples were collected simultaneously during the experiment.
Effect of exogenous vasoactive intestinal polypeptide-Five other healthy men with no erectile complaints (aged 21-52) volunteered for this study. All gave written informed consent after the study had been approved by the local ethical committee. Local cavernous blood flow was continuously determined by a "33Xe washout technique.6 13 Tumescence was measured with a strain gauge around the penis.6
Highly purified, sterile vasoactive intestinal polypeptide '4 (20 and 200 pmol) in saline or saline alone was administered as a bolus into the cavernous body in randomised order via a 27 gauge needle without preceding anaesthesia.
Statistical analysis was by Wilcoxon's test for pair differences; p values less than 0 05 were considered to be significant.
Results
Release of vasoactive intestinal polypeptide-Eight of the nine men showed an increase in the median concentration of vasoactive intestinal polypeptide in the cavernous blood during erection ( minutes. The penis remained slightly enlarged for several hours. A significant decrease in the local cavernous elimination of "33Xe and a significant increase in penile circumference were found in all cases (table II) .
Discussion
In the present study the concentration of vasoactiva intestinal polypeptide in cavernous blood was shown to increase up to 20-fold during penile tumescence and erection. This change must be due partly to local release of the polypeptide, as the concentration of the polypeptide in the peripheral circulation was unchanged throughout the experiment, and partly to the simultaneous decrease in cavernous blood flow, as a constant release of the polypeptide accompanied by a decrease in local blood flow would lead to an increased concentration. The observed changes in local blood flow during tumescence and erection, however, were not of sufficient magnitude to account for the total From the results of this and previous studies we conclude that vasoactive intestinal polypeptide fulfils several of the classical criteria for a neurotransmitter in penile erection in man: it is present in nerve fibres with nerve endings around cavernous smooth muscle and blood vessels7 -9; it is released when erection is induced; and when applied exogenously it mimics the action of the endogenously released transmitter and displays identical pharmacological characteristics.8 9 The recent observation that phenoxybenzamine (an alpha adrenoceptor blocking agent) injected intracavernously produces full rigid erection in normal and in certain imp-otent men is of interest,'6 as this compound alsohas a relaxing effect on cavernous smooth muscle. Thus vasoactive intestinal polypeptide, papa- 11 verine,'°and phenoxybenzamine may possibly have a role in diagnostic procedures for erectile dysfunction. None of the drugs, however, should be recommended yet for general therapeutical use.
